Pyoderma Gangrenosum

  • Daniel Wallach


Pyoderma gangrenosum (PG), one of the most impressive cutaneous conditions, is an inflammatory ulceration with a distinctive clinical appearance, often associated with systemic diseases. Considerations on the significance of pyoderma gangrenosum, both in its classic ulcerative form and in its clinical variants, led to its inclusion among the spectrum of the neutrophilic dermatoses. Ongoing research aims at identifying genetic factors favoring PG, as well as deciphering the mechanisms of inflammation in PG.



I am indebted to Professor Frank Powell, MD, for fruitful and friendly discussions, in addition to his outstanding writings and lectures on pyoderma gangrenosum.


  1. 1.
    Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166–70.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985;55:173–86.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Powell FC, Collins S. Pyoderma gangrenosum. Clin Dermatol. 2000;18:283–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43:790–800.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses. Br J Dermatol. 2015.
  7. 7.
    Brocq L, Simon CL. Contribution à l’étude du phagédénisme. Bull. Soc Méd. Hôp. 1908;25:290–307. Paris 3eme série.Google Scholar
  8. 8.
    Brocq L. Nouvelle contribution à l’étude du phagédénisme géométrique. Ann Dermatol Syph. 1916;6:1–39. 5ème série.Google Scholar
  9. 9.
    Cullen TS. A progressively enlarging ulcer of the abdominal wall involving the skin and fat following drainage of an abdominal abscess apparently of appendiceal origin. Surg Gynecol Obstet. 1924;28:579–82.Google Scholar
  10. 10.
    Brewer GE, Meleney FL. Progressive gangrenous infection of the skin and subcutaneous tissues, following operation for acute perforative appendicitis: a study in symbiosis. Ann Surg. 1926;84:438–50.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Tixier, Pollosson, Arnulf. La gangrène post-opératoire progressive de la peau et son traitement. Presse médicale. 1937;64:1163–4.Google Scholar
  12. 12.
    Brunsting LA, Goeckerman WH, O’Leary PA. Pyoderma (ecthyma) gangrenosum. Arch Dermatol Syphilol. 1930;22:655–80.CrossRefGoogle Scholar
  13. 13.
    Greenbaum SS. Phagedaena geometrica (Brocq). Arch Dermatol Syphilol. 1941;43:775–801.CrossRefGoogle Scholar
  14. 14.
    Liu JW, Hsu NY, Huang TC. Pustules and bacteraemia. Lancet. 1997;350:860.PubMedCrossRefGoogle Scholar
  15. 15.
    Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79:37–46.CrossRefGoogle Scholar
  16. 16.
    Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165:1244–50.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395–409.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    O’Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol. 1978;114:1061–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg. 1991;78:676–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Fenske NA, Gern JE, Pierce D, Vasey FB. Vesiculopustular eruption of ulcerative colitis. Arch Dermatol. 1983;119:664–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Arch Dermatol. 1972;106:901–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Ho KK, Otridge BW, Vandenberg E, Powell FC. Pyoderma gangrenosum, polycythemia rubra vera, and the development of leukemia. J Am Acad Dermatol. 1992;27:804–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Jacobs P, Palmer S, Gordon-Smith EC. Pyoderma gangrenosum in myelodysplasia and acute leukaemia. Postgrad Med J. 1985;61:689–94.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Wilson-Jones E, Winkelmann RK. Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol. 1988;18:511–21.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Langan SM, Powell FC. Vegetative pyoderma gangrenosum: a report of two new cases and a review of the literature. Int J Dermatol. 2005;44:623–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Rashid RM. Seat belt pyoderma gangrenosum: minor pressure as a causative factor. J Eur Acad Dermatol Venereol. 2008;22:1273–4.PubMedCrossRefGoogle Scholar
  27. 27.
    McGarity WC, Robertson DB, McKeown PP, Amerson JR, Darden WA. Pyoderma gangrenosum at the parastomal site in patients with Crohn’s disease. Arch Surg. 1984;119:1186–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Zuo KJ, Fung E, Tredget EE, Lin AN. A systematic review of post-surgical pyoderma gangrenosum: identification of risk factors and proposed management strategy. J Plast Reconstr Aesthet Surg. 2015;68:295–303.PubMedCrossRefGoogle Scholar
  29. 29.
    Tolkachjov SN, Fahy AS, Wetter DA, Brough KR, Bridges AG, Davis MD, et al. Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. J Am Acad Dermatol. 2015;73:615–22.PubMedCrossRefGoogle Scholar
  30. 30.
    Lê Huu S, Spertini F, Roggero P, Egloff DV, Raffoul W. Pyoderma gangrenosum: a rare pathology or an omitted diagnosis? Ann Chir Plast Esthet. 2009;54:82–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Kitagawa KH, Grassi M. Primary pyoderma gangrenosum of the lungs. J Am Acad Dermatol. 2008;59:S114–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Field S, Powell FC, Young V, Barnes L. Pyoderma gangrenosum manifesting as a cavitating lung lesion. Clin Exp Dermatol. 2008;33:418–21.CrossRefPubMedGoogle Scholar
  33. 33.
    Roujeau JC. Neutrophilic drug eruptions. Clin Dermatol. 2000;18:331–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Lewerin C, Mobacken H, Nilsson-Ehle H, Swolin B. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy. Leuk Lymphoma. 1997;26:629–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Tinoco MP, Tamler C, Maciel G, Soares D, Avelleira JC, Azulay D. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47:953–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Yurci A, Guven K, Torun E, Gursoy S, Baskol M, Akgun H, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19:811–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Crittenden SC, Gilbert JE, Callen JP. Hydroxyurea-induced leg ulceration in a patient with a homozygous MTHFR polymorphism misdiagnosed as pyoderma gangrenosum. JAMA Dermatol. 2014;150:780–1.CrossRefPubMedGoogle Scholar
  38. 38.
    Peterson LL. Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol. 1984;10:379–84.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Pralong P, Debarbieux S, Paret N, Balme B, Depaepe L, Nosbaum A, et al. Recurrent pyoderma gangrenosum-like ulcers induced by oral anticoagulants. Ann Dermatol Venereol. 2014;141:34–8.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Jiménez-Gallo D, Albarrán-Planelles C, Linares-Barrios M, Rodríguez-Hernández C, Martínez-Rodríguez A, García-Moreno E, et al. Pyoderma gangrenosum and Wegener granulomatosis-like syndrome induced by cocaine. Clin Exp Dermatol. 2013;38:878–82.PubMedCrossRefGoogle Scholar
  41. 41.
    Perry HO, Brunsting LA. Pyoderma gangrenosum; a clinical study of nineteen cases. AMA Arch Derm. 1957;75(3):380–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Rudolph BM, Staib F, Von Stebut E, Hainz M, Grabbe S, Loquai C. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma—simultaneous occurrence of pyoderma gangrenosum and colitis. Eur J Dermatol. 2014;24:268–9.PubMedGoogle Scholar
  43. 43.
    Pinato DJ, Sharma R. Imatinib induced pyoderma gangrenosum. J Postgrad Med. 2013;59:244–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Boudny C, Nievergelt H, Braathen LR, Simon D. Wegener’s granulomatosis presenting as pyoderma gangrenosum. J Dtsch Dermatol Ges. 2008;6:477–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Del Pozo J, Sacristán F, Martínez W, Paradela S, Fernández-Jorge B, Fonseca E. Neutrophilic dermatosis of the hands: presentation of eight cases and review of the literature. J Dermatol. 2007;34:243–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Lebbé C, Moulonguet-Michau I, Perrin P, Blanc F, Frija J, Civatte J. Steroid-responsive pyoderma gangrenosum with vulvar and pulmonary involvement. J Am Acad Dermatol. 1992;27:623–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Farrell AM, Black MM, Bracka A, Bunker CB. Pyoderma gangrenosum of the penis. Br J Dermatol. 1998;138:337–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Kennedy KS, Prendergast ML, Sooy CD. Pyoderma gangrenosum of the oral cavity, nose, and larynx. Otolaryngol Head Neck Surg. 1987;97:487–90.PubMedCrossRefGoogle Scholar
  49. 49.
    Storwick GS, Prihoda MB, Fulton RJ, Wood WS. Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J Am Acad Dermatol. 1994;31:336–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Rose GE, Barnes EA, Uddin JM. Pyoderma gangrenosum of the ocular adnexa: a rare condition with characteristic clinical appearances. Ophthalmology. 2003;110:801–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Newman WD, Frank HJ. Pyoderma gangrenosum of the orbit. Eye (Lond). 1993;7:89–94.CrossRefGoogle Scholar
  52. 52.
    Wilson DM, John GR, Callen JP. Peripheral ulcerative keratitis—an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet’s syndrome with an excellent response to cyclosporine therapy. J Am Acad Dermatol. 1999;40:331–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Su WP, Schroeter AL, Perry HO, Powell FC. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol. 1986;13:323–30.PubMedCrossRefGoogle Scholar
  54. 54.
    Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen J, Wollina U, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 2018.
  55. 55.
    Wong WW, Machado GR, Hill ME. Pyoderma gangrenosum: the great pretender and a challenging diagnosis. J Cutan Med Surg. 2011;15:322–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Hadi A, Lebwohl M. Clinical features of pyoderma gangrenosum and current diagnostic trends. J Am Acad Dermatol. 2011;64:950–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med. 2002;347:1412–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Hafner J, Nobbe S, Partsch H, Läuchli S, Mayer D, Amann-Vesti B, et al. Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriolosclerosis. Arch Dermatol. 2010;146:961–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Nguyen KH, Miller JJ, Helm KF. Case reports and a review of the literature on ulcers mimicking pyoderma gangrenosum. Int J Dermatol. 2003;42:84–94.PubMedCrossRefGoogle Scholar
  60. 60.
    Harries MJ, McMullen E, Griffiths CE. Pyoderma gangrenosum masquerading as dermatitis artefacta. Arch Dermatol. 2006;142:1509–10.PubMedCrossRefGoogle Scholar
  61. 61.
    Burton JL. Sweet’s syndrome, pyoderma gangrenosum and acute leukaemia. Br J Dermatol. 1980;102:239.CrossRefPubMedGoogle Scholar
  62. 62.
    Caughman W, Stern R, Haynes H. Neutrophilic dermatosis of myeloproliferative disorders. Atypical forms of pyoderma gangrenosum and Sweet’s syndrome associated with myeloproliferative disorders. J Am Acad Dermatol. 1983;9:751–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Benton EC, Rutherford D, Hunter JA. Sweet’s syndrome and pyoderma gangrenosum associated with ulcerative colitis. Acta Derm Venereol. 1985;65:77–80.PubMedGoogle Scholar
  64. 64.
    Davies MG, Hastings A. Sweet’s syndrome progressing to pyoderma gangrenosum—a spectrum of neutrophilic skin disease in association with cryptogenic cirrhosis. Clin Exp Dermatol. 1991;16:279–82.PubMedCrossRefGoogle Scholar
  65. 65.
    Vignon-Pennamen MD, Wallach D. Cutaneous manifestations of neutrophilic disease. A study of seven cases. Dermatologica. 1991;183:255–64.CrossRefPubMedGoogle Scholar
  66. 66.
    Wallach D. Les dermatoses neutrophiliques. Presse Med. 1991;20:105–7.PubMedGoogle Scholar
  67. 67.
    Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol. 1956;68:385–94.PubMedCrossRefGoogle Scholar
  68. 68.
    Radcliffe-Crocker H, Williams C. Erythema elevatum diutinum. Br J Dermatol. 1894;6:33–8.Google Scholar
  69. 69.
    Wallach D, Vignon-Pennamen MD. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol. 2006;55:1066–71.CrossRefPubMedGoogle Scholar
  70. 70.
    Moschella SL. Review of so-called aseptic neutrophilic dermatoses. Australas J Dermatol. 1983;24:55–62.PubMedCrossRefGoogle Scholar
  71. 71.
    Wallach D. The neutrophilic dermatoses. Overview. In this volume.Google Scholar
  72. 72.
    Cohen PR. Neutrophilic dermatoses occurring in oncology patients. Int J Dermatol. 2007;46:106–11.CrossRefPubMedGoogle Scholar
  73. 73.
    Scerri L, Zaki I, Allen BR. Pyoderma gangrenosum and subcorneal pustular dermatosis, without monoclonal gammopathy. Br J Dermatol. 1994;130:398–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Cartier H, Plantin P, Leroy JP, Larzul JJ. Pyoderma gangrenosum, subcorneal IgA pustulosis and recurrent neutrophilic pleural and pulmonary diseases in a patient with IgA gammopathy. Ann Dermatol Venereol. 1995;122:97–101.PubMedGoogle Scholar
  75. 75.
    Caucanas M, Heylen A, Rolland F, Müller G, Olemans C, Sass U, et al. Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet’s syndrome: the concept of neutrophilic disease. Int J Dermatol. 2013;52:1185–8.CrossRefPubMedGoogle Scholar
  76. 76.
    Mendoza JL, García-Paredes J, Peña AS, Cruz-Santamaría DM, Iglesias C, Díaz Rubio M. A continuous spectrum of neutrophilic dermatoses in Crohn’s disease. Rev Esp Enferm Dig. 2003;95:233–6, 229–32.PubMedGoogle Scholar
  77. 77.
    Ayres S Jr, Ayres S 3rd. Pyoderma gangrenosum with an unusual syndrome of ulcers, vesicles, and arthritis. AMA Arch Derm. 1958;77:269–78.PubMedCrossRefGoogle Scholar
  78. 78.
    Vignon-Pennamen MD. The extracutaneous involvement in the neutrophilic dermatoses. Clin Dermatol. 2000;18:339–47.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    McCulloch AJ, McEvoy A, Jackson JD, Jarvis EH. Severe steroid responsive pneumonitis associated with pyoderma gangrenosum and ulcerative colitis. Thorax. 1985;40:314–5.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Vignon-Pennamen MD, Zelinsky-Gurung A, Janssen F, Frija J, Wallach D. Pyoderma gangrenosum with pulmonary involvement. Arch Dermatol. 1989;125:1239–42.PubMedCrossRefGoogle Scholar
  81. 81.
    Fukuhara K, Urano Y, Kimura S, Hori K, Arase S. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol. 1998;139:556–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Holt PJ, Davies MG, Saunders KC, Nuki G. Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore). 1980;59:114–33.CrossRefGoogle Scholar
  83. 83.
    Wright V, Watkinson G. The arthritis of ulcerative colitis. Br Med J. 1965;2(5463):670–5.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175(5):882–91. Scholar
  85. 85.
    Schaen L, Sheth AP. Skin ulcers associated with a tender and swollen arm. Pyoderma gangrenosum (PG) in association with chronic recurrent multifocal osteomyelitis (CRMO). Arch Dermatol. 1998;134(9):1146–7, 1149–50.PubMedCrossRefGoogle Scholar
  86. 86.
    Yoshida C, Kojima H, Ishigaki T, Katsura Y, Kaneko S, Suzukawa K, et al. Association of pyoderma gangrenosum and sterile osteomyelitis in a patient having myelodysplastic syndrome with der(1;7)(q10;q10). Eur J Haematol. 2004;72:149–53.PubMedCrossRefGoogle Scholar
  87. 87.
    Claudepierre P, Clerc D, Cariou D, Lavabre C, Venencie PY, Bisson M. SAPHO syndrome and pyoderma gangrenosum: is it fortuitous? J Rheumatol. 1996;23:400–2.PubMedGoogle Scholar
  88. 88.
    André MF, Piette JC, Kémény JL, Ninet J, Jego P, Delèvaux I, et al. French Study Group on Aseptic Abscesses. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore). 2007;86:145–61.CrossRefGoogle Scholar
  89. 89.
    Maringe E, Gueudry J, Joly P, Muraine M. Nodular scleritis associated with pyoderma gangrenosum. J Fr Ophtalmol. 2015;38:171–3.PubMedCrossRefGoogle Scholar
  90. 90.
    Linck V, Sanchez B, Baubion E, Molinie V, Deligny C, Quist D, et al. Pyoderma gangrenosum and neutrophilic aortitis preceding the development of rheumatoid arthritis. Ann Dermatol Venereol. 2015;142:425–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Marie I, Levesque H, Joly P, Reumont G, Courville P, Baudrimont M, et al. Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis. J Am Acad Dermatol. 2001;44:137–9.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Koester G, Tarnower A, Levisohn D, Burgdorf W. Bullous pyoderma gangrenosum. J Am Acad Dermatol. 1993;29:875–8.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Chanson P, Timsit J, Kujas M, Violante A, Guillausseau PJ, Derome PJ, et al. Pituitary granuloma and pyoderma gangrenosum. J Endocrinol Invest. 1990;13:677–81.PubMedCrossRefGoogle Scholar
  94. 94.
    Urano S, Kodama H, Kato K, Nogura K. Pyoderma gangrenosum with systemic involvement. J Dermatol. 1995;22:515–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Carvalho LR, Zanuncio VV, Gontijo B. Pyoderma gangrenosum with renal and splenic impairment—case report. An Bras Dermatol. 2013;88:150–3.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Dinulescu M, Vigy P, Droitcourt C, Adamski H, Rioux N, Bretagne JF, et al. Pyoderma gangrenosum and aseptic pyosalpinx in a pregnant patient. Ann Dermatol Venereol. 2007;134:179–80.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Al Ghazal P, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13:191–211.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Decherd JW, Leyden JJ, Holtzapple PG. Facial pyoderma gangrenosum preceding ulcerative colitis. Cutis. 1974;14:208–10.Google Scholar
  100. 100.
    Schlick K, Regauer S, Beham-Schmid C, Cerroni L, Rohn A, Deutsch AJ, et al. Pyoderma gangrenosum heralding acute leukemia for months: diagnostic hint written on the skin. J Clin Oncol. 2011;29:e506–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985;80:615–20.PubMedGoogle Scholar
  102. 102.
    Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87:281–93.CrossRefGoogle Scholar
  103. 103.
    Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45:202–10.CrossRefPubMedGoogle Scholar
  104. 104.
    Salmon P, Rademaker M, Edwards L. A continuum of neutrophilic disease occurring in a patient with ulcerative colitis. Australas J Dermatol. 1998;39:116–8.CrossRefPubMedGoogle Scholar
  105. 105.
    Seitz CS, Berens N, Bröcker EB, Trautmann A. Leg ulceration in rheumatoid arthritis--an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature. Dermatology. 2010;220:268–73.PubMedCrossRefGoogle Scholar
  106. 106.
    Vignon-Pennamen MD, Aractingi S. Sweet’s syndrome and leukemia cutis: a common skin homing mechanism? Dermatology. 2003;206:81–4.PubMedCrossRefGoogle Scholar
  107. 107.
    Sujobert P, Cuccuini W, Vignon-Pennamen MD, Martin-Garcia N, Albertini AF, Uzunov M, et al. Evidence of differentiation in myeloid malignancies associated neutrophilic dermatosis: a fluorescent in situ hybridization study of 14 patients. J Invest Dermatol. 2013;133:1111–4.CrossRefPubMedGoogle Scholar
  108. 108.
    Haga N, Iwata H, Yamaguchi Y, Shirato T, Nishimura K, Yamane N, et al. Mucocutaneous pyoderma gangrenosum due to trisomy 8 neutrophilic infiltrates in a patient with myelodysplastic syndrome. Br J Dermatol. 2016;174:239–41.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum and monoclonal gammopathy. Arch Dermatol. 1983;119:468–72.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    de Boysson H, Martin Silva N, de Moreuil C, Néel A, de Menthon M, Meyer O, et al. French Vasculitis Study Group, French Internal Medicine Society. Neutrophilic dermatoses in antineutrophil cytoplasmic antibody-associated vasculitis: a French multicenter study of 17 cases and literature review. Medicine (Baltimore). 2016;95:e2957.CrossRefGoogle Scholar
  111. 111.
    Ujiie H, Sawamura D, Yokota K, Nishie W, Shichinohe R, Shimizu H. Pyoderma gangrenosum associated with Takayasu’s arteritis. Clin Exp Dermatol. 2004;29:357–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol. 2008;144:392–402.PubMedCrossRefGoogle Scholar
  113. 113.
    Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 2011;63:314–24.PubMedCrossRefGoogle Scholar
  114. 114.
    Butler D, Shinkai K. What do autoinflammatory syndromes teach about common cutaneous diseases such as pyoderma gangrenosum? A commentary. Dermatol Clin. 2013;31:427–35.PubMedCrossRefGoogle Scholar
  115. 115.
    Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73:691–8.CrossRefPubMedGoogle Scholar
  116. 116.
    Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc. 1997;72:611–5.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Nesterovitch AB, Hoffman MD, Simon M, Petukhov PA, Tharp MD, Glant TT. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol. 2011;36:889–95.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    DeFilippis EM, Feldman SR, Huang WW. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol. 2015;172:1487–97.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Brooklyn TN, Williams AM, Dunnill MG, Probert CS. T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br J Dermatol. 2007;157:960–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Caproni M, Antiga E, Volpi W, Verdelli A, Venegoni L, Quaglino P, et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol. 2015;173:275–8.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Quaglino P, Fava P, Caproni M, Antiga E, De Simone C, Papini M, et al. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group. J Eur Acad Dermatol Venereol. 2016;30:655–8.PubMedCrossRefGoogle Scholar
  122. 122.
    Oka M. Pyoderma gangrenosum and interleukin 8. Br J Dermatol. 2007;157:1279–81.PubMedCrossRefGoogle Scholar
  123. 123.
    Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178:48–56.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1996;34:1047–60.PubMedCrossRefGoogle Scholar
  125. 125.
    Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646–54.PubMedCrossRefGoogle Scholar
  126. 126.
    Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, et al. Dermatology Clinical Trials Network’s STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Greco DJ, Wright ET. Pyoderma gangrenosum; report of a case controlled by cortisone. AMA Arch Derm. 1956;74:543–6.PubMedCrossRefGoogle Scholar
  128. 128.
    Li J, Kelly R. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2013;69:565–9.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273–83.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol. 2007;157:1235–9.PubMedCrossRefGoogle Scholar
  131. 131.
    Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–9.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Jacob SE, Weisman RS, Kerdel FA. Pyoderma gangrenosum—rebel without a cure? Int J Dermatol. 2008;47:192–4.PubMedCrossRefGoogle Scholar
  133. 133.
    Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199–201.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173:1216–23.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Patel F, Fitzmaurice S, Duong C, He Y, Fergus J, Raychaudhuri SP, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol. 2015;95:525–31.PubMedCrossRefGoogle Scholar
  136. 136.
    Wenzel J, Gerdsen R, Phillipp-Dormston W, Bieber T, Uerlich M. Topical treatment of pyoderma gangrenosum. Dermatology. 2002;205:221–3.PubMedCrossRefGoogle Scholar
  137. 137.
    Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol. 2004;150:1052–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Daniel Wallach
    • 1
  1. 1.Physician (Hon.) of Paris HospitalsParisFrance

Personalised recommendations